bioli20220809

0001437749-22-019616.txt : 20220809 0001437749-22-019616.hdr.sgml : 20220809 20220809162008 ACCESSION NUMBER: 0001437749-22-019616 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 221148637 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20220809_8k.htm FORM 8-K bioli20220809_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2022

BIOLIFE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36362		94-3076866
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of exchange on which registered
BioLife Solutions, Inc. Common Stock	BLFS	NASDAQ Capital Market

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the second quarter ended June 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated August 9, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BioLife Solutions, Inc.

Date: August 9, 2022	By:	/s/ Troy Wichterman
		Name: Troy Wichterman Title: Chief Financial Officer

EX-99.1 2 ex_409284.htm EXHIBIT 99.1 ex_409284.htm

Exhibit 99.1

BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance

Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46%

Updating 2022 revenue guidance to $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and higher organic growth expectations of 37% to 43%

Sequential improvement in adjusted gross margin; on track for continued improvement in 2022

Positive adjusted EBITDA in Q2 2022 of $1.5 million

BOTHELL, Wash. (August 9, 2022) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (“CGT”) and the broader biopharma markets, today announced financial results for the three and six months ended June 30, 2022.

Mike Rice, Chairman and CEO, commented, “Our team delivered another quarter of very strong business performance, with substantial revenue growth, and, importantly, sequential gross margin and adjusted EBITDA improvements as we continued to address operational issues with our ultra-low temperature (“ULT”) freezer product line.”

“Our high margin biopreservation media line continues to deliver exceptional growth, with the second quarter being another quarter of 40%+ year over year growth. As we move past ULT freezer issues, we are now recognizing a non-cash impairment charge against these assets. This adjustment does not limit our view of the unique differentiation of the technology that will be a catalyst for growth with innovative ULT freezer product launches in 2023.”

Troy Wichterman, CFO, added, “The second quarter of 2022 was noteworthy for continued strong growth performance alongside significant fundamental improvements and operational progress in our ULT freezer business. Demand for our portfolio is strong, as evidenced by record revenue, strong organic growth, improved gross margin and positive $1.5mm in adjusted EBITDA this quarter, compared to negative $814,000 for the first quarter of 2022. As such, we are tightening our full year 2022 full year revenue guidance.”

Operational Highlights

●

For the second quarter of 2022, we gained 202 new direct customers sites including 17 now using biopreservation media, 10 using ThawSTAR_^® systems, 11 now using evo_^® cold chain management services, 10 now using CBS cryogenic freezers and accessories, 110 new sites now using Stirling ULT freezers and accessories, 30 now using SciSafe_^® biologic storage services and 14 now using Sexton cell processing products.

●

For the second quarter of 2022, we processed 23 new U.S. FDA Drug Master File cross-reference requests, indicating the planned use of CryoStor_^® or HypoThermosol_^® in pending cell and gene therapy clinical trials. To date, our biopreservation media products have been used or are planned to be used in more than 550 customer clinical applications, including 10 approved cell and gene therapies, and in at least 10 additional therapies for which regulatory filings are expected to be submitted in 2022 and 2023. We estimate potential annual biopreservation media revenue per approved commercial application to range from $500,000 to $2 million.

●

Use of evo cold chain by CGT end customers continued to increase in Q2 2022, with courier partner shipment volume up nearly 100% over Q2 2021. Our evo cold chain platform is currently used to store and transport two approved CAR T-cell therapies and we anticipate two additional global pharma companies will commence use of evo this year for the storage and shipment of an additional four approved CAR T-cell therapies. By mid-2023, we expect the evo platform will be used for all six currently approved CAR T-cell therapies. This adoption validates our belief that the evo platform will increasingly be selected as a class-defining temperature-controlled shipping container and related cloud app by the leading CGT companies.

●

Biological storage services revenue increased significantly in Q2 2022 as we onboarded 30 new customers. We expect to commence construction and validation of a nearly 60,000 square foot US-based Center of Excellence Biorepository by the end of 2022 to meet anticipated demand for our high growth, highly profitable biologic storage services.

●

ULT freezer quality continued to improve in Q2 2022 and product lead times were reduced from twelve weeks to less than two weeks despite continued supply chain disruptions.

Second Quarter and First Half 2022 Financial Results

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

REVENUE

●

Total revenue for the second quarter of 2022 was $40.5 million, an increase of 30% from $31.2 million for the second quarter of 2021, with organic revenue growth of 44%. COVID-19 related revenue accounted for approximately 9% of total revenue.

Cell processing platform revenue was $15.4 million, up $5.7 million, or 58%, over the same period in 2021. Biopreservation media growth was 46% and organic growth was 46%.

Freezers and Thaw Systems platform revenue was $18.7 million, up $1.1 million, or 6%, over the same period in 2021. Organic revenue was up 23%. COVID-19 related revenue is estimated at 4%.

Page 2 of 13

Storage and Storage Services platform revenue was $6.5 million, up $2.6 million, or 65%, over the same period in 2021. Organic growth was 65%. COVID-19 related revenue is estimated at 45%.

●

Total revenue for the six months ended June 30, 2022 was $76.8 million, an increase of 60% from $48.1 million for 2021, with organic revenue increase of 45%. COVID-19 related revenue accounted for approximately 9% of total revenue.

Cell processing platform revenue was $30.3 million, up $11.6 million, or 62%, over 2021. Organic growth was 49%.

Freezers and Thaw Systems platform revenue was $34.0 million, up $11.6 million, or 52%, over 2021. COVID-19 related revenue accounted for approximately 4% of the freezer and thaw systems platform revenue. Organic growth was 9%.

Storage and Storage Services platform revenue was $12.5 million, up $5.5 million, or 78%, total and organic growth over the same period in 2021. COVID-19 related revenue accounted for approximately 48% of the storage and storage services platform revenue.

GROSS MARGIN

●

Gross margin (GAAP) for the second quarter of 2022 was 33% compared with 39% for the second quarter of 2021. Adjusted gross margin (non-GAAP) for the second quarter of 2022 was 36% compared with 43% for the second quarter of 2021 and 33% in the first quarter of 2022.

●

Gross margin (GAAP) for the six months ended June 30, 2022 was 31% compared with 43% for the six months ended 2021. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2022 was 34% compared with 47% for the six months ended 2021.

●

The decline in gross margin in both periods was primarily due to a shift in product mix after the acquisition of Global Cooling, Inc. (Stirling Ultracold), which has lower gross margin than the remainder of BioLife’s portfolio. The sequential quarter improvement in GAAP and non-GAAP gross margin was primarily due to improvement on our ULT platform as well as favorable product mix.

OPERATING EXPENSE

●

Operating expense (GAAP) for the second quarter of 2022 was $116.8 million compared with $35.8 million for the second quarter of 2021. Adjusted operating expense (non-GAAP) for the second quarter of 2022 was $20.0 million compared with $13.3 million for the second quarter 2021.

●

Operating expense (GAAP) for the six months ended June 30, 2022 was $160.6 million compared with $53.6 million for the six months ended June 30, 2021. Adjusted operating expense (non-GAAP) for the six months ended June 30, 2022 was $39.8 million compared with $22.2 million for 2021.

Page 3 of 13

●

The increase in GAAP operating expense was primarily due to a non-cash impairment charge of $69.9 million related to the acquired intangible assets of Global Cooling, Inc. (Stirling Ultracold). Adjusted operating expenses (non-GAAP) increased due to the full period of ownership from the acquisition of Global Cooling, Inc. on May 3, 2021, and the acquisition of Sexton Biotechnologies, Inc. on September 1, 2021. In addition, operating expenses increased due to increased accounting costs related to becoming a Large Accelerated Filer and additional headcount to support our growth.

OPERATING INCOME/(LOSS)

●

Operating loss (GAAP) for the second quarter of 2022 was $76.3 million compared with operating loss of $4.6 million for the second quarter of 2021. Adjusted operating loss (non-GAAP) for the second quarter of 2022 was $5.4 million compared with adjusted operating income of $65,000 for the second quarter of 2021.

●

Operating loss (GAAP) for the six months ended June 30, 2022 was $83.9 million compared with operating loss of $5.5 million for the six months ended June 30, 2021. Adjusted operating loss (non-GAAP) for the six months ended June 30, 2022 was $13.4 million compared with adjusted operating income of $560,000 for the six months ended June 30, 2021.

NET INCOME/(LOSS)

●

Net loss (GAAP) for the second quarter of 2022 was $72.6 million compared with net income of $7.9 million for the second quarter of 2021. Adjusted net loss (non-GAAP) for the second quarter of 2022 was $5.5 million compared with adjusted net loss of $56,000 for the second quarter of 2021.

●

Net loss (GAAP) for the six months ended June 30, 2022 was $79.6 million compared with net income of $6.8 million for the six months ended June 30, 2021. Adjusted net loss (non-GAAP) for the six months ended June 30, 2022 was $13.5 million compared with adjusted net income of $422,000 for the six months ended June 30, 2021.

EARNINGS/(LOSS) PER SHARE

●

Loss per share (GAAP) for the second quarter of 2022 was $1.71 compared with earnings per diluted share of $0.19 for the second quarter of 2021. The non-cash intangible impairment charge accounted for a $1.65 loss per share.

●

Loss per share (GAAP) for the six months ended June 30, 2022 was $1.89 compared with earnings per diluted share of $0.17 for the six months ended June 30, 2021. The non-cash intangible impairment charge accounted for a $1.65 loss per share.

Page 4 of 13

ADJUSTED EBITDA

●

Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2022 was $1.5 million compared with $3.7 million for the second quarter of 2021.

●

Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2022 was $679,000 compared with $6.5 million for the six months ended June 30, 2021.

CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

●

Cash, cash equivalents, and marketable securities as of June 30, 2022 were $46.6 million compared to $59.5 million as of March 31, 2022. The use of cash in the second quarter was primarily related to changes in working capital of $12.4 million, which includes a $7.0 million increase in accounts receivable and a $3.1 million increase in inventories. In addition, capital expenditures were $2.0 million in the second quarter of 2022, primarily related to build outs of our biorepository facilities.

Page 5 of 13

2022 Revenue Guidance

Management is updating 2022 revenue guidance, which is based on expectations for our existing business.

Total revenue for 2022 is expected to range from $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and organic growth of 37% to 43%. COVID-19 related revenue is expected to account for approximately 8% of total revenue.

Total revenue expectations for 2022 include the following platform contributions:

●

Cell Processing platform: $67.0 million to $69.5 million, an increase of 49% to 55% over 2021 and organic growth of 42% to 47%. This includes biopreservation media and Sexton products.

●

Freezers and Thaw Systems platform: $70.0 million to $71.5 million, an increase of 24% to 26% over 2021 and organic growth of 31% to 34%. COVID-19 related revenue is expected to account for less than 5% of the freezer and thaw systems platform revenue in 2022. This includes ThawStar thawing devices, cryogenic liquid nitrogen freezers and ULT Stirling freezers.

●

Storage and Storage Services platform: $23.0 million to $25.0 million, a total and organic increase of 31% to 42% over 2021. COVID-19 related revenue is expected to account for approximately 41% to 45% of the storage and storage services platform revenue. COVID-19 related storage revenue is primarily generated from contracts, including contracts that extend beyond 2022.

Although the Company does not provide guidance below the revenue line, we expect positive 2022 full year adjusted EBITDA.

Conference Call & Webcast

Management will discuss the Company's financial results and provide a general business update on a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. The conference ID number is 2389359. A webcast replay will be available approximately two hours after the call and will be archived on https://www.biolifesolutions.com/ for 90 days.

Page 6 of 13

About BioLife Solutions

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor_^® and HypoThermosol_^® biopreservation media for shipping and storage, the ThawSTAR_^® family of automated, water-free thawing products, evo_^® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company following the completion of its 2019, 2020 and 2021 acquisitions and giving effect to the COVID-19 pandemic, the Company's ability to implement its business strategy and anticipated business and operations, in particular following its recent acquisitions and the construction and validation of a center of excellence biorepository, the expected synergies between the Company and the companies and products that it has recently acquired, the Company’s ability to realize all or any of the anticipated benefits associated with its recent acquisitions, the Company’s ability to address and resolve ULT freezer issues, the potential utility of and market for the Company's products and services, including the adoption of evo cold chain services by all six currently approved CAR T-cell therapies, and the Company’s ability to cross sell its products and services, guidance for financial results for 2022, including regarding revenue of its recently acquired products, and potential revenue growth and changes in gross margin, adjusted gross margin and adjusted EBITDA margin, and potential market expansion, including with consideration to our recent acquisitions and giving effect to the COVID-19 pandemic, the Company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from our recent acquisitions, market adoption of the Company’s products (including the Company’s recently acquired products), the ability of our recent acquisitions to be accretive on the Company’s financial results, the ability of the Company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Non-GAAP Measures of Financial Performance:

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

Page 7 of 13

*Media & Investor Relations*

At the Company Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors

LHA Investor Relations

Jody Cain

(310) 691-7100

jcain@lhai.com

Page 8 of 13

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(In thousands, except per share and share data)	2022			2021			2022			2021

Product revenue	$	34,170		$	27,468		$	64,558		$	41,244
Service revenue		3,698			1,963			6,787			4,167
Rental revenue		2,665			1,773			5,407			2,640
Total revenue		40,533			31,204			76,752			48,051
Costs and operating expenses:
Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)		26,194			18,554			50,640			26,104
Research and development		3,428			3,045			7,209			5,032
Sales and marketing		5,415			3,142			10,306			5,164
General and administrative		11,351			7,146			22,546			11,974
Intangible asset amortization		2,863			1,882			5,725			2,815
Acquisition costs		5			272			16			1,271
Change in fair value of contingent consideration		(2,361	)		1,718			(5,695	)		1,226
Intangible asset impairment charges		69,900			-			69,900			-
Total operating expenses		116,795			35,759			160,647			53,586
Operating loss		(76,262	)		(4,555	)		(83,895	)		(5,535	)

Other income (expense), net
Change in fair value of warrant liability		-			-			-			(121	)
Interest expense, net		(9	)		(121	)		(173	)		(137	)
Other expense		(22	)		-			110			(1	)
Total other expense		(31	)		(121	)		(63	)		(259	)

Loss before income tax benefit		(76,293	)		(4,676	)		(83,958	)		(5,794	)
Income tax benefit		3,739			12,552			4,338			12,552
Net (loss) income	$	(72,554	)	$	7,876		$	(79,620	)	$	6,758

Net (loss) income attributable to common shareholders
Basic and Diluted	$	(1.71	)	$	0.20		$	(1.89	)	$	0.18
Diluted	$	(1.71	)	$	0.19		$	(1.89	)	$	0.17
Weighted average shares used to compute earnings (loss) per share attributable to common shareholders:
Basic		42,460,189			38,072,712			42,238,355			35,668,124
Diluted		42,460,189			40,390,098			42,238,355			38,275,603

Page 9 of 13

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share amounts)

	Three Months Ended					Six Months Ended
	June 30,					June 30,
(In thousands)	2022			2021		2022			2021

NET INCOME/(LOSS)	$	(72,554	)	$	7,876	$	(79,620	)	$	6,758
Other comprehensive income/(loss)		(462	)		3		(618	)		3
COMPREHENSIVE INCOME/(LOSS)	$	(73,016	)	$	7,879	$	(80,238	)	$	6,761

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

	June 30,			December 31,
(In thousands)	2022			2021
Cash, cash equivalents, and marketable securities	$	46,575		$	69,870
Working capital		84,759			85,478
Total assets		470,379			554,057

Long-term obligations		24,767			33,539
Accumulated deficit		(184,640	)		(105,020	)
Total shareholders' equity	$	412,313		$	480,137

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

	Six Months Ended
	June 30,
(In thousands)	2022			2021
Net cash used in operating activities	$	(17,841	)	$	(5,902	)
Net cash used in investing activities		(27,340	)		(8,643	)
Net cash (used in) provided by financing activities		(470	)		385
Effects of currency translation		(190	)		3
Net increase (decrease) in cash, cash equivalents and restricted stock	$	(45,841	)	$	(14,157	)

Page 10 of 13

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(In thousands)	2022			2021			2022			2021
GAAP GROSS PROFIT	$	13,246		$	12,064		$	23,926		$	20,774
GAAP GROSS MARGIN		33	%		39	%		31	%		43	%

ADJUSTMENTS TO GROSS PROFIT:
Inventory step-up		251			733			251			765
Intangible asset amortization		1,093			586			2,186			1,173
ADJUSTED GROSS PROFIT	$	14,590		$	13,383		$	26,363		$	22,712
ADJUSTED GROSS MARGIN		36	%		43	%		34	%		47	%

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(In thousands)	2022			2021			2022			2021
GAAP OPERATING EXPENSES	$	116,795		$	35,759		$	160,647		$	53,586

ADJUSTMENTS TO OPERATING EXPENSES:
Cost of product, rental, and service revenue		(26,194	)		(18,554	)		(50,640	)		(26,104	)
Acquisition costs		(5	)		(272	)		(16	)		(1,271	)
Intangible asset amortization		(2,863	)		(1,882	)		(5,725	)		(2,815	)
Loss on disposal of assets		(162	)		(15	)		(257	)		(18	)
Change in fair value of contingent consideration		2,361			(1,718	)		5,695			(1,226	)
Intangible asset impairment charges		(69,900	)		-			(69,900	)		-
ADJUSTED OPERATING EXPENSES	$	20,032		$	13,318		$	39,804		$	22,152

Page 11 of 13

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

(Unaudited, amounts in thousands)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(In thousands)	2022			2021			2022			2021
GAAP OPERATING INCOME/(LOSS)	$	(76,262	)	$	(4,555	)	$	(83,895	)	$	(5,535	)

ADJUSTMENTS TO OPERATING INCOME:
Inventory step-up		251			733			251			765
Acquisition costs		5			272			16			1,271
Intangible asset amortization		2,863			1,882			5,725			2,815
Loss on disposal of assets		162			15			257			18
Change in fair value of contingent consideration		(2,361	)		1,718			(5,695	)		1,226
Intangible asset impairment charges		69,900			-			69,900			-
ADJUSTED OPERATING INCOME/(LOSS)	$	(5,442	)	$	65		$	(13,441	)	$	560

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

(Unaudited, amounts in thousands)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(In thousands)	2022			2021			2022			2021
GAAP NET INCOME/(LOSS)	$	(72,554	)	$	7,876		$	(79,620	)	$	6,758

ADJUSTMENTS TO NET INCOME/(LOSS):
Inventory step-up		251			733			251			765
Acquisition costs		5			272			16			1,271
Intangible asset amortization		2,863			1,882			5,725			2,815
Loss on disposal of assets		162			15			257			18
Change in fair value of contingent consideration		(2,361	)		1,718			(5,695	)		1,226
Change in fair value of warrant liability		-			-			-			121
Income tax benefit		(3,739	)		(12,552	)		(4,338	)		(12,552	)
Intangible asset impairment charges		69,900			-			69,900			-
ADJUSTED NET INCOME/(LOSS)	$	(5,473	)	$	(56	)	$	(13,504	)	$	422

Page 12 of 13

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(In thousands)	2022			2021			2022			2021
GAAP NET INCOME/(LOSS)	$	(72,554	)	$	7,876		$	(79,620	)	$	6,758

ADJUSTMENTS:
Interest expense/(income), net		9			121			172			137
Income tax benefit		(3,739	)		(12,552	)		(4,338	)		(12,552	)
Depreciation		986			1,118			2,639			1,895
Intangible asset amortization		2,863			1,882			5,725			2,815
EBITDA	$	(72,435	)	$	(1,555	)	$	(75,422	)	$	(947	)

OTHER ADJUSTMENTS:
Share-based compensation (non-cash)		5,973			2,520			11,372			4,024
Inventory step-up		251			733			251			765
Acquisition costs		5			272			16			1,271
Loss on disposal of assets		162			15			257			18
Change in fair value of contingent consideration		(2,361	)		1,718			(5,695	)		1,226
Change in fair value of warrant liability		-			-			-			121
Intangible asset impairment charges		69,900			-			69,900			-
ADJUSTED EBITDA	$	1,495		$	3,703		$	679		$	6,478

# # #

Page 13 of 13

EX-101.SCH 3 blfs-20220809.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 blfs-20220809_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 blfs-20220809_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 blfs-20220809_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image01.jpg begin 644 image01.jpg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end

XML 8 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	Aug. 09, 2022
Document Information [Line Items]
Entity, Registrant Name	BIOLIFE SOLUTIONS, INC.
Document, Type	8-K
Document, Period End Date	Aug. 09, 2022
Entity, Incorporation, State or Country Code	DE
Entity, File Number	001-36362
Entity, Tax Identification Number	94-3076866
Entity, Address, Address Line One	3303 Monte Villa Parkway
Entity, Address, City or Town	Bothell
Entity, Address, State or Province	WA
Entity, Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	false
Title of 12(b) Security	BioLife Solutions, Inc. Common Stock
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Amendment Flag	false
Entity, Central Index Key	0000834365

XML 9 bioli20220809_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2022-08-09 2022-08-09 false 0000834365 8-K 2022-08-09 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway Bothell WA 98021 425 402-1400 false false false false false BioLife Solutions, Inc. Common Stock BLFS NASDAQ EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20220809/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20220809_8k.htm blfs-20220809.xsd blfs-20220809_def.xml blfs-20220809_lab.xml blfs-20220809_pre.xml ex_409284.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20220809_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20220809_def.xml" ] }, "inline": { "local": [ "bioli20220809_8k.htm" ] }, "labelLink": { "local": [ "blfs-20220809_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20220809_pre.xml" ] }, "schema": { "local": [ "blfs-20220809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20220809", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20220809_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.blfs.com/20220809/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20220809_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220809/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-019616-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-019616-xbrl.zip M4$L#!!0 ( (*""54E%!W6$0X 'I= 4 8FEO;&DR,#(R,#@P.5\X M:RYH=&WM'&MSVKCV\W;F_@==.NTF,S&81]) TLQ00K+%$M"CDJE>OU>FF*, 4#U)!LF &<#J2G02NVO56"U@00&UP^A\W"F<8$ MU*?<";.0(7.*(W%>TDW0IU).C\M7HE M<3]4U'?8'#YT\R@#V'+IS^.CGC-F M$YH \ZFR8.I,AP05[GO<9W]^ZAZ5E*1^.!1R0A47/HQ5WK3L;:NZ0!) OZUF M*+:FILRGYKKY*E9E:\Y!X?O1)'\<5\F2F@6L!$ 60#')G:1?%%K8M&#^D(8# MW2MIT;RW['**N$A)-EHI@7H)VA?$K8(K5U,$IM"1PEN!CFY!=.PL.J$*9+[R M8$M&=RY)):LZV#R@X5QU>"AJE?*'JY3-0,S%<+T,LOS7=J!RC633&(E:Z#&_ M7H^M9>U7X\AWF73%A&5Z=_@ZRU:C8C6J%G!T3R]I[LSMABA+$R&+?(W[^L= 2OF*^ MLOI@&@7BF*>/!<6FJF2<3FEOMV20W!T(=T9"-?- DX< :H7\?ZQ!RG:@=HA^ M,:03[LT:Y/WW2*B=/I^PD)RP"](5$^J;ESLDH*X+>M\@-O>)72QS?X> 6$(A M&X1&2NP 6UQ^GLSD\C#P* P*JR%O2'U0K9;R@QQZS';/@AKUH)! M)?4Z()GI9S8K[-GP9[M:JVYM7IX IB@M$P%>G*&:LA!?X*K8"+5)P[Q$.Z_& M6,R,FD7!W0>*B ME6D*%\_PA3%7*\$*+:<["%,=*&5TL@=K"[YNT^J;MXOU]..OWV/NGUF_UV;[$8UD0E_ VR7VP52<7> MK-6O0^[YZ=/!:?>8W&[)W1=.A*NX=F$XQK;UV4@VN]+>1-K/CZ%@ ]WV29]T MVV>GW?X3TGC [0R=H0&U)_Q$C348AKN5ZMO4 E0Q>*Y'=9 /$G64N>&04'RD)%V#GT(U(W,W>] M<2/[-KGVQP(DYPT71IP T-BELQD,R_P\^S_3OKMM?+J653,:13!_?8/@J/EK MPHL2U5UBV2X;\1#+'^H$6C1?/W5.CSH';=([/?K2!S_:VR"=DU;Q+@Q^),+7 MVE,*1HJTH6K*.4V$AB0,F(,QJ$L@'^$J)H*ER_=&U0]&!QX $SXMSI(\% MNZ"?PX ZR?,MV;A!].L-$H)$ACE,O>"N&N.#_2[AF^6QH3+,2]Y(/AJKA)^8 MBT+.B@GAWJZ2]XT23H#CN\G R$AQ+8&0BDQ :!@2D+(E%TB1X,U>X/@?^L[ MY)Q)Q1WJ)G3:2T/6]M;6S=3&?B5^O<1?-%+EO.:]@&8H0G(S"3Y&W*AT.4F=1/#W8$D)8TU M3SN.]:=OXR]:J"TQF? P1!GBRDV,(;Y*[6E+K=/MD?8D\,0,##&[DI(34Y:::KBM9&,8_1]QG9>VBJE6[2HYQ!/(?[GF4G%'Y M[8+.&;4@#Z <];3?3=9]*NYE2>07K"<0\; M!_S:S)OI1V8Y$Y $>?_EP3RCJ6_;E?)="\B/5<^(L<=B1B"!/3R@'F%3YD2* MGV.- Y8"%JZ3-:",(&F/7\SXN1Q:E*W>O]VNE#_LA-#)8\%8^(SXVL%M$&"< M%V&=A4 &2T%O7)@75&#M=@J%-M&$ >8J5*MLYBG0^BT5]4B ;SM#C%.A<=@U,*'>MSAN4@]Y-2,R7> M_-SGFO@H0\B<58])Q]H!@$&X8@JQ4A>DX)&:U0P,PMJGF.\"HY4 7D\B3U&?B2CT9B2$(#(K/DK:A\&!R[(?%18Z91=AX5@XH)87YW^K6G0NQ R&\ 06F@1Y/TR[@J^0* MY(096N3'T7V(E-8_U&H[EP*A&!PF3<.3(+71VHU@M08'%4L-Q97:T\2MS+7R M!](ZZ))*U2X"X/.*'!Y+<#WP*@[PU!\=@T4"$MYJJ2U@ 3T#?%EDY1JURI64 MU#+;SW.9U>RB@7P5VUW$=B89VAJ>D--G2G")E*?#(09?J\0'?2PGU>E:ZRO7 M7*NR-EB_F3 -[*LX[T&<_ N@"_T6A2%3$,!$G%XCS>7N([EF%*6>RYOAY!< M:)$, G;H!Y9%?0=#$>KHRQL(C-=)7"K=T 3V.'Z0>XAOC2;']S(F4R1S#7A& M$L\*-[5:&%$QN8I-.@B(V03<>?P4Z9>MW21GEH+I3HR^I0$:9FM^_M(1'EXK MN?E.?:5<+#] ?2YS%')!TP>X^&X=5[;?=P J%L%S??S=D"+2N'>6#: M)=4%UW V&0CO1F3_TK(^B8\L(Z,(DM40C?$I<2TVRYZV2L.RHX/>C[+D53OS@V=<#"X?N4PT-PF8 MYN>M3YJ]_>:_5^RQDA8-.%[[/(88D:DK]PA^=J%K>=!O=QN$>A=T%B8J:FZO+IVU'C-#504]6^R]DK6##*CS#1*#R'>M M;!/>YEQBP1_[^2Q /MZ9 ?W3UA%^)>$J%EP;7E]2HVO/PZ2#:;),S%-+Y,#^ M.HI-2*5HZ\.M!KO;_@NC=%D8>4KOYY\&3,9%)DBVR,$\#VL)R NQH?BL;QFM M8/6I3[+W>3;(*J_.L^#.6$JDTIN9>K&,::$I&>GO$R1[GA@M)GMWUQ:1GIO$$^.J%^WR#QG7 MPH3TF2(LYQJ!QQ((7Z1!K;GK!J&$"Z_5AUN>'+EQ>&O@YYZX_K '2!)Y+Y\@ MB>6\,"4,+44Q/V*\ZICM$CDZA[[WZQ/+/+-_#M/V6>A('J!7^-'C-YDLYV?H M #J:AY3TE?3^%/E18CZ3PJ9_U>QZ9;N&']29KR.8BUDPA*2.@IQ,6P?T.DM[ M[0WBZD_M+-\EID];%3)L*-NU9R7V#'$M ?.3,SIB$/Q!7 :RQ!.P^U11P2?X^XC'.=FYUCV,C;7G9HA+O!.C>-7= J5[ MI^8A18I?V&E<"HGO*L@'U\!/L\;5V-W'#?\'W] KA272EV)&OG)G#$X5QGC: MQG/_!K.4ESP\SW$+KK&"ZP]^0J1!6F/.AJD=@%-]K4\^B-A_=H[S"/, B3&% M^&G;O?\#4$L#!!0 ( (*""54:[,4!=P, "X. 1 8FQF"DW;1$3:MJW:I(W0^MK;2WB6"2H&%P M :_M?[\#&]=NG=;)I&E/P?!]W'?'<5R.3NYRB7YS8X56\V0\2A/$%=.94.MY M76U*E7%SIG.. MOFGCJ$08O2=3,DDG$_1N-DEGAX?HVV>,/?O.9C/+-CRG""0H.[M;&BGFR<:Y M8D;([>WMR,^,M%G#!ND!$)MUT+<'$3LF/SY?7(:]&[ 4ZE#I 3E>*!V2N*Z;>_2VI%B,TXZ)?-"P$S3>'$=A/X?$$'XQ'8#HA.VN8$J,E)!M? M^RL_3(Q?C=/BKZ+^ 0(6WFEXJXNY9MU[I/@-V*#R/L1W\7@OW< M_RO?GU21@;D8"=[LVWV"W2Y'@Z+]0/!#7 WWL=RM;(-LMRGQ8Y?SWE(LAV59 M#?>#O6T^*KG#G&YSFJ^]);3*^"#S#3Z,NF9KPU0I[<(>40HM"J%6VG_Z1W<6 M7][O?(5"4S"CAOGR]7SK0 JC"VZ(<--H:OYHE_ 7"L_C\E78[@;8J0 M)P:Z53R43Z!P>?$@+W+]G9XG%F(J>17B?^E(QE>[.@(4H80_A/_.F\+P7;T! MBH6F@.[FCZ=>P1(2T,+"Z^Q"9X$SS69U_5 M<1@S*EDIFZC6I!K11^AFUW\4?NS^AD#!/&IPK-H'[&OBO/D!8R04 Y\A#]3 M,P$I )UI2,)J!C3!/[L%S'NW($W#+%P2H;.K@,M*4YDAC9-5_87//U!+ P04 M " ""@@E567HX9=P$ !0+0 %0 &)L9G,M,C R,C X,#E?9&5F+GAM M;,U:76_B.!1]7VG_0S;[' *TG2UHF!&BS AM.T6%T:[V9>4D%[#&L5G'*?#O MUPX?I4/L&-I$>8$0'U^?XX^;F]-^_+R.B?,,/,&,]MQ6H^DZ0$,683KON=\G M7G\R&(U<)Q&(1H@P"CV7,O?SIU]_^?B;YWT%"AP)B)Q@XTP7*8V W[$8G#'C M A''M!VB" M\X R:,O_^^%^$BX@1AZF:DI"Q27!W22[><]")+)Y+)3@:!'JE[>'>>J6UVI[ M5ZW&.HG]G*[<(#_'6:#WKTZ&00%0'JNKGG+AJC,R_C1G%3+)G^SE<+J;K=*HY>5 MF:* 0 [#(FBU+.7>A)'<:HD=TQ-XB6SO88[(=CW[:YQ'4(.H8 :G<@C#C!TW M5\!F#!RS:$BC.YDU#+1R<:6?U2>8XT1P1,4W%.?1,\%*9S>2=35?,IYM[XE* MNP.64L$W Q;IR5KU*IW[%TS@6WI<7IT0/864SFJ*UJ-(/:EF>%MY%U LP)?. MMQ]%'))D]Z4R7$O+U8"MBN= 7C[R*5OI'W]:9%4/MZYB1J 9> M%=LQD^46^0!"Z1J5K$/@>DX9;77.8S608EXP6C^KRC@Y3(ZB^.A2Q\ M!RR.4[I+(GGU@A%7(K\)(SB4KP)T_B W.L>(Y)#3@TID-N:@9@/DJ9X8Q\+EEST.'<7FN>VY3 M]LKS55+(K!]WQ15.BO, OSX$759;IV-QD5L!9#DCU_>FX"=X3A5NS+P_#;Q-VJGE8B&G75LY!JO&0M=5[705>SP6LJYK*NL,-\A"Y4U- M5>JL) M)'VHJR&ULS5MA;^HV%/T^ M:?_!8U\VJ6D*[9[6JNU3U?8]H=$6%:I->YJFD!BPEO@RQ[3P[V<[0 G8(:'8 MV9<2XIMS;LX]B:])>OEYEL3H%;.4 +UJ-(]/&@C3$")"1U>-EYYWT[MMMQLH MY0&-@A@HOFI0:'R^_OZ[RQ\\[RNFF 4<1V@P1_WQE$:8W4&"41<8#V+DH5_] M<[]UTFJA3Q>MDXNS,]1]\#QY=$SH/Q?RSR!(,1)9T%1]O6J,.9]<^/[;V]OQ M;,#B8V C 7%RZB^C&XMP.1KQU0'KP;_XV> J= OZ[53%-L_/SWTUN@I-B2Y0 M@#;]/QXZO7",D\ C5$H2REQ2VT;&*%(?'(WCU(TSD#-7\]TQN>MFF MREY\_?N>F_)Y-/\X8ME0M8N"./180?@I@/)SQ_#D,& M28%4L$N#[)0$A1+R@(7MB*LGSGAO9B35U-804;&\&RBV*ZSHT++.DM%ME4VB M00DUK-7Z#L)I@BEOTR&P1/5HXFZ#VQPGNL*7":_H@B)(VY98PW)4\HQ7=0X0D M<2W5U\L(I?6QYH>L:WG&(Y)R%E#^&"0Z.Q2%[;4RR$.Y62$]FD$-F5:W))'"&5!@*& M%JD@F4L-5BJG.NPIIV6C?2$Q?IPF \R,KMH.V5C!@NO*%H$=Y_OIJ*R;9?_<1)&0 M.%U\R 5ST^B=@MB]?*/!<^69!>=J ZE?.)YH'1-.D:Q022\W7KD5FT^L#V_F MW[B-D1_QR3N:A44UA'_$ M)QN0SLVR:F27&=3G&).Z.ML4RN;&.UU(>1#_22:%RZ*BX(_X)@?HW#49.Q+T M=2U\"G75.:9 ,&M^D3>W&X8#@T-TPQ4]L0YAVP5J7I%D[FNN50IV26#O":LH M3]P= S4O7TTA59^Q;L!8?\@J^9 BK&-=8E0-RLAAK=Z_,\(YIK>0)%.Z6/[H M'J\6QE6LO!;+=OD7I"C/ZM0"Q1I":7&LF:$',0D))W3T('H01H)8XP1S4$4; M; /9]L [(UI2.C5 @7103A-KI>\R+"V'1?[JD9U\*8L]#8?:&6!W<$4KF %M M6T(P>^$:-,LP7KW#Y9!O\;%YEU MUGMIAX"6EY_W"68C<>_[RN"-CT5>DX#.C>O/PNB]%J!:1%PQHE9VQ3X]WMM/I:J M<>)*&Z3ZA7SXV#X^ODYNCOGX>9NQX F$I#SOA:U&,PP@3WA*\T4O_#Z)^I/! MN%1JU8WCS6;3 MV,X$:W"QP"::5_$1'1[@NC15IPKGX/?QOO $?='TYLI@6YU.)S:E)ZBD14!L MM!7_>3^:)$O(2$1S+4FBN4C:E>;FB"=$&1TKAQ!8$?HJ.L(B?2MJM:.K5F,K MT_ DG. ,'F$>Z./WQ^&S'F=L+AL)SXSNS9MF)]:H&/DJR"!742_4K47'EC2)WU[=D-JM,&PDS58,PO@TAI4 B94, M=(0W#FA-MI;Q[&G 5@&&Z9F6C"?/1JR[EL=XDI T%OPI3H'J_EO_7.O3:']J MY,#+O^],IQCYA)ZZ8V0&K!?:BO=LF X9+LY4^1_8C&!!V+[/_I;* D(61(V< M;@]S-/QO7J9DQJ" 7!7TLBPQ,F&(@58DHPO\ FRGV$4)N_/B"[ 9@Z \O&HGZU2K=NY?*(-OZVP&PDKT):1V5E.R':;ZG3"G^Y=S!<4*?.U\^VF*KT5Y M..BG2% M,UL-OAS3H91K$*_B:ZU2^W/F+@.QP(G]*OA&+9'3BN0[ZX.F%%UGE$*RQ@6R M:[5G4ZH*OQ-LD!I93071SLADE\UXT;(I++^ 2G?;9$GR!5ARVC)8C>SZ&.BI M#O8OC"P*:!66UQ[_ ^Q0$#;$E;?] ^R1;\'9^)V[&7V1!%S@RNZ%S3# $ES? M M+1O@NK]6-L#<,#.S/V53=A7$+:"Y58GV:,B.2%1_*\H0,B7A&A;9%D25EZ MK#T7/"LW 7B5:8'-FX&_W:%76@S9*L.%K2;'IZDJU6NMYL8GJ2GK@:[FRB>9*JO<_'=I/$J6W78+W!3 MQ9.$M7R3PDT*3U+5DLT1-QT\24ZK=V/<'#-/TM*272 W'3S)2QUVGU]:UO;R++NYSV_HC+8#3L(: BQ, MUNSSZ3RRW,::R))'DB%>O_Y4M2Z6+[(-D76C9J\=P);4K>KJJKC[FK M,FVDV@YW/QQ,W>'QR8'_J:F.^8>#H66/5?=XP%VNN;IE'C#-,EUNPM4N-_AD M9)G\@VD=G/WR_JTWY?=]:S!CCCLSQ.VF>^SH_^'OF%R=N*=,?#!4Q[HQ>\?^ M\??49OQL\JW_6_3'2^[K+VNV*_/YM_^S] M6[P*?DS.?GG&; T^W/=D_V'VGWW\P%0#UE_#R!-XJF,DBB:*OM_1RI_.7D15@*O'GHVKKJNF^,Y%AC=/(N!IP M*[=/O7'?(1=F,R:PQT?=NM*'G/4L8XJ[R6%W? )[U&$]#OMJP/XU56VXD8F] M^DDW55/380/?<6=JP%4J7/)M,H"M[K!/4\-@_Y>K_L5W_)&;4\X^3_4!W,4] M[HM_OQ6.B;YA->8-DZ-AW C;:*B?W0&E[ &S_?>UANRW>K728#"B 21ENJG9 M7'5 &-:J;YCU"-3\EX(TDB7VI+LC9MD/JJEKX1,>;.L)/QZR>OV-('%?MR8V MAYWSJ.(JL3$?Z.JZZYMOWK_5RTEFP68@?SWN"M_=YR[F6NPWN5D-J>[]W0S^ MEN".H8$J YXP R8]QH4XQM\B]*L!O>'&6MLC^PAD-*Q6L#[^=?S'!)ZC>ML% M;VJ)F^JU\M*^Q_^>PC>X\_7QQ ;2C>%/X&RF#OZ:.JCH@3B.X\O24X8+8*O: M=Q#SME#0.BS68/EFL9(E)!H+_E\^"2AX:SFZJS_R.<&Z'R_O+SI(!D\:*$)R MR!'!D0?*Y)_Z2$Y].%M5;3?W7[I75Q+[4W5&%7;8F3[ E:PM"6(?,=1'__CU M1)'E4[B:O9^N*L/W;Z=G$KLT-;C]6G4&ZM_OV,>K3[TCO)<=XMU*]=2_3?PE M ^O;S!UQYG]Y;HTGJCGSOSR2F JH0T4ZB1<*Z6\-I@+O,O]73_>B2M UH-[0'U;CH(3QFP> X/B)K4YT^#Z8 M[/GG^V NXC*\IV];*@!T,0X@[[&*V_@[=P&LN=9 G<&%IC4%(3M@PQ !V#X" M" 9V1S;GWIST'VP,:S9R& ?@/V#_G,)4:E6/\)42>$22@$#<\C&.2$+"VV(VL%QID!=#]; :P*+V.JQ83W! M"X_%=5.;A\SX[6K.C$-@G__ F_OLS0QXX8K_;0E9)L(*B#*"=5@/]) 6(>T= MI+W/.8!%-#[Q:1^LNB ^;DG'@_ !3_4Y"I,UG%:OOOD_ A-YX#2"B2JL(]9] M#%^ _0OB$Y8L7"IOL26\0(55-6&5;1CRP=3_(T:"3\QC#:0OLA)N"U3[:-L_ MP T/JF["\V N#OSE@+GO5-C]2'=\/A07#RQX79@P4& ,1BQRU*,.RP"3QA>< MFCJP,QOHPR'L(F1K033_6Y=K(],RK(<9_*FZ0!<0C7T8C&FJJQHS&!V%EX_J M!-5T$'1(>7C;Z(N&/*F"%(0)^]BE5F+^O+>M&?M3UT; (_!($&R?0);!EH_( ML?M5'@/2"RCSI(IUXT\@>D:S)13H"S6?\!&1!F8^?.'H W@NS$P?ZAI,F0VG MYD!%?EB$GYX&C$H?^.I!B"18'^25Z!H&(K3"+O@8;\0YX44H'8<6 "[@9W]J M$HH[_@CS$$JO/Q-\/;?QI. 5%BT#*9C=8%6X3@+\APAO/%Z SKZ\=9'Y?4(* MM3%1;4_2FOS!8\K?3N2Z5*U60ZT[U&U@XR7JBUWK3+51N#5==#9Q 2;PE8=H MJ<]"2WW^Y[)556(&!\QW$V&=+T A ZGDI.RG<-6^ 1 ,N(O;'PZJ!P+!^:[& M\&]GHFK!W_Z4GO2!.X(!JV].GT&I ^&C_:_WK@V_X,_!TO-.%F;H#I8O P7A MPJXT?-*ZUN1TX4YQ^;[H]FN[V6I[A,-A=IO>ICFQ97(MNR7]#X)9,7]:_LY& M?Z&[Z%(,>.W@[)._1==+2+$U40?"#H>_88L_@1X#,0,:$AYAC;D->UAWA;+1 MC*FP&.264+(HR1[60P4)9NU_?S]2GWKWG;OW@!#/X)$T$]NU8%\^#O^V_?7 MV0%5R,>@R&4Y\GS^:&V_5;., :IT$&= /O7!,^T#JT3,9O[$\X\]IMDS"TP3 MD)F^8/:DN*K!Y8YEZ^(FO OHX;W^_/Z>J]L&_A*1ZVMNKT7'[&EZ3QWR[6\" MY 2H /,"XMOP(G/3"@>0Z]%GPGH#P86I!?(>A\:/ \.LLLR@\!.WVR_P$S=[ M6I)EH#]ZEN2'@]O/'_]8DAQ,B([ ^8V><)^;_4]$?$)\A&&-A6=]NK\+'Q;E M?=\/PB(#+-T[&AZ#IES]4)#R]O/UMZ_S=Q#._,4?O[P?V<' MYW/W>./=]W. M'\>=3_?=NW< 'I[4F7/JRU+^@ MMP%L'"]^M4* +Q?K">#%$U[X^OZ^7TC 59#'#\5=-D@Q_!55OGI9X(Q M**@VTLW!_#&(E: PTT,U41%/75$>.<<=%@/M,1VI0+3_3*;6& HV6/+ ML8SM=X BG7!3:/MUKKP92 W=Q-5@+I#/0)O98AA_DP2R7^\_"%V&(Q6,B#[G M)K[* %V5:!T$KP>6!IC'XAO4YQ8:#B/59(U&-00E\_%5]%=J7AA$BH*4*G[E MF4$QWDCAF1(FD(O>4+!@\";8GCX8G[LMT0!@W.)*PU=F?<#4PTAB(!>:8Z[O!X-6G\&-SA$TX:<.7 M0H>>+9R@$1K@!&S5!. PM*TQ^ZU1K0I+#>-02N#2SPLT( %94@'YS9-0@-U9 M!)KW9^S\\SUZXR/&Q8(O-XA11\)1OB-1 [&"88D)B%H3?CHC?2) _J-E3,<@ M+B8@957;F G LQ#>KC!T;R[-!82-B_X>]+9H4QO==G"O$#HP#P3?7A3!A8YE("KT=/![R0ID]P?XM[Y@+EP;#ZZ!_RHAO"M6+J MPD\-S_$<]!H/Q#M.6/ABA$LD\+0$9H&(< 0T@*O1U3\?:(A">.-D*^SC#,3! MX!B%DM!8G@@3@^#0(8$"?Z6@#4Y#A;\QN#(GVY:1?'>J)3S$[!&XQI[1]4/[/ $B $9"VR#2?00 #46N!T'\W6[-Y0[L#<>U_? N;@]_I_JQ M##40L$T/43@(>P%F6);+OO6.^V)2Y\+VQLN[/Y -Q8/AO6PN/,\(F_PMAEH@ M<-/#+,:XB$X%_FW\ R8"0F>H^[LASFU"FY8V[7ZA3B2X SO" MT-W9$J;Q@C$+.Q0C,4$P#U0-<\7\GL A(T.'Z.F1?CN/G$#;GWB_+N(MQH8 M51+&$"(+[^,!=R:Z&PV*BQR.F0]T!KIC3X7FS*%G\1B2F+62IXOI^$B&Q M+ZHQC$E:]=*JBIZ,NI8HJ^F\ "%76L*9P8^SIHZD32>,7=M77.82-'W?"5> M\KX!C-S1,+L &!M^L:;>(VYMT(3ZQ,"X6=W_S[\N)8;H?F8'"=ZHF;P.Q%(_>'\-N!3&J_$4(A^I)Y4:_YVE*-^MZV MU L$X +5K()LI?/E"&_@'PD856P?N5&IS[?/=,)^:U1:\P^ @QLG;R3/,R:V MC#H6'F7="KS4<@5-M37^YR W#8:I-[TS"4N'$?RO: O0%MA/Q"V:9H$I):SG M98O$;8:3*._C9I K\L)F:&[="S=+:@,?#$]2:IMT!H#$(+HS0 19S\V>*&@> MQBUZ<\2A%+E&V1B4C5&2; S2"3^M$WJ14%CP>R_PEZ]7"\VHA8%:0:DT%[5" M8V>U$$$^<-=S5$(C-SHA7WN"K.]]6]\;C\1Y6Z35K)S$6N'-T JOG\SQE'C^ M!GL[^H3ZQJU"%C>IECQLG]TL[EJU4ELR,N1E?:($^B16>=3;I Z(C_-A-M?J ME>H6CFXLH? 88).S 37[AW:.K1U\F-=R,JR>=&(?@"[ MH(4>6 _"K'&B;K8[7K;13L*=MI YN)Q>M++; MN5[;-K(0)3AE&"W^%'A.) EMM=>XU;8[/&KR1L9??L!S=]P.$ZBO3*"U;0*T MIVA/[=5]")PWX)HH^ .,O<#E>)#'\@JF #YU! ]/; "<-LR*#::B!J**1RZ& MHKI>D.@Z!DY6AZX/<57M[ZGNZ&$RGGZS?AZ9TCR3^' M-X)1#>N)VXN3\W)C1YA&.U9UD4P(3X^41I-;I\Z\U@J>3>'1:E2!\EJJ$"CR M U';AN MV>]VC+$029#\MR/S:.EA'Y,>$FPY_!AC_398CL9 E'?U;K1'Y M;F>$;JW.YUDP_3>E.O?0+4])KLW]T7$/(_A NRX'NVZ'0*3"?)MW1[H:OOJHS5I/\I)Z@0/?2O7[] M.3"NPQ*WHJA.\(P>'MH;]P%TRH$&OIQ7J9#6O=_*2\T_4.=G_S3+<9TH_?N M<<=>K=\KL5AX8M#P6_]@C27;KRP=%LC ECSB>:+:QW0B*GR@B>X7',Z)FD[? M]KZ\/K_YVGU[>'73P_KR9(&30$[*%C#08_8,\[O5C)BSB^#:6GRHZ'6SSB#8 MW1SW)O<\6SQRX&II?NKJ "#)L/.84".-A>+),;/,B0BBC?DZ-^8.UN])+0*' MMF[02"[,SUCLL1MU%Y="[84[MN'7O-EQWCG9NFFAA^ON/>$&$D_)BJ=K[CX? M,2BQ'D.3N]$-W8I(KIW1@AE.Z;DXH;%-ZH2/]J0-X0/:@+G=@+L<(FKONA&; MZZ)HNZ*"C1MR-SRPT\Z,S+>N*(0$8I% MW-W?7G]N>?C ';;O6.]+YT[BN63 M0/II@71E>9WGF#/"PI//">176O+2_N:J;8KJW?C @6Y,75$F%A^,V[Q:D=M; M@0'ZFN<>X[G;=TV;L<44?9Q1L^&)KO"%\B(K:/^\SOVSB[ZLG+2?O8]:.^OU MS9N?CGM]Y]]\+O8TB(DS3FSVK,SF)K3,G/$/"K MQ:K.U.;2C@ TSL[\K38O5$8>'V+WXK#[#G@1WETX2Y98OOG\2%!.6#\M77;> MZ7V1&/[+NO_Z=OGOSE7W^K['.M<7>$;YC^Y]Y^-5E_6ZY]_N+N\ONSU2=K3[ M?[KF#5A=$A.V%_][JC^J!C:W]K*_X/;OW%MYT$U36W=%OR,1KEC:]]C#X+=Z M\]X*MJ:R-6\Y+$%,\,]'L@^9;@.J6XF,$7208#$]%\$+ED M[,FROXN$,76B8\T%M$AE)5HFUSM,YG6-PS?"R-#\?$4TD= W.3'O3.- '9'? MATEEJ,+EM;?HYB.04+2#74I]"R8D$M_@0Y"L?ON'WY2%\3>V&5S[^OVI;@R8 M-?7R#OUF?)'V*T,5J^"[.>IGM#<#&>W8G0UD8>\V%NS= EJXZ\S5U%8Q*8.T MH$K;:P4BI."=7YKEL]_ OL2]/K[.^VWK6!]YX"7/"#*$!?=],H3RUF%>NRB0 M<5XC*J]_9]CMB?_0'?&8/K:ZYHY3QF8;JS4:!=&P7&BDFVBTF:?A8] Z<]SO 6@-P(Q8565=_""YHB0OJ6VM<1V;H M:\8UU8=.XDHVEGDA5QC:6U4/8GA9^I9A6$\+=05%KT*][W7+>4=PGN!\(B4L M;U=+6+Y#L[RR*$>:[0V=5^IM(1(:C3?SLG\QTJ.N>-*C]<9O^AD"Z_5]C45M M->\42= ;.B^@E/9%2??%]I*8L$-:U:4=TI(W[!#%TZI*<_L.P6I#J( W]AW: MH%_G#0 ;SR^A&30C7]Z<2(6>J]KB;I05 RZJ H*=:L^L!XZO8.A_ XACIN[: M^$DPJ$=&K&L2GF4+OJ&=3#LY^PJ=L)F5VM)F5AK1*K?JFH*<"YW'O"V+NFV7 MLK<[@^.Z_]S&"RMTKDXAN"OVX M@>K8_+#/9^A^RE,QO]1BRH8[LJ8/([$\YZ(1^(P-+!C&M%S$+(_Z8&[>8C-S MZ\DO/^4M 5;0BG97%VXX_9%[1H$XKBM,-'4Q]%)$*VF-+^3<,H?<%CV@S[%K M_#_4\>24_V3PV)&=8#$,X_)G]I/G(4ENP.):J=\8?OUYM7PN/ M<;#'LNKZ[S0]&[GNQ'GW]NW3TU,%NX_##4YP?46SQF^#S#@@\O1LT?V/@RPO MH&"4/O^B!K@#U0,KN681PCLF*')]7J$6O)C>/V24L6>F5@C;'!C"8> M%&"RPV:]><1JU19HB&9-7*>CV]M4_2/P_L5>O"4RF\L+9D[%L7W0'TKMI%UK MM+&#;L!8-@=5-)O/]U'5#2\:LJ#>L$$UR$Z<35CT+^34\&9;&P'3HB-P=\(B M/;VK\:7:50:,GJJ#,$W(5N%,5*!C+ M@1BZ%V@5+'T\X*"K13@"W5C"4>79$I;A"=L0I0?I+"*)%+]!)8Z?V.ID)C[H MVY:*94GQ42,5YNL'UT$0WTQM_YEA@=*YD8YA$1@; #T'4WT6BLMS,-'1^D&I M^-Z9]O&?"5AR@PRO,H9GG)O$?-U<_( $Q/J]JNCN+.$ "XRIP;^#(\ZFL5O*9:ZDQ MQY0$-)K#FR,W:GI/'?+YU:CRK(?(@ %O>9D8>,O:NCL"96A+?8L$-U78)UBQ ML66C PA-2-5#(1/1QIX]8DD??&Z'"1 MF#F,$7PY9THO)A**(7@_9*0GW04^P"O+"%5](TGUA= =?U!M(8%@O9[@5W9E M62)_I>?"=D">+;-4!E)T?VA\XOE*1CKRO]@T$:85'@K8QH 808!Q76!IX>9 MP&]SCZ/]BX0T1CH>&SX=G9".(A/13Z\9/ F M<,>%$Z8#MCPBKW:[(0"TPS<-Y@MQ"4PYE^'1&/0>&/I8]YQ$4O1:F+S&A>4@ M9A/ZDN;6XH3;@B (UOTY!ZZ)>631,S'&L,>#GG*[$%_%$6YAD/T6/@F4^AL@G$&?*QKTI(UJ_8QK6CF5[XV_(P &#,T7QT7 M_4\/GAH$QM U?2(<4N$5P@7GU=^ R4BB>KB*_L:IH=J1E]/]-"P8867VOFT% M@_E:&C]\!+X;J $E5!]0X^_\!\I,8?@LY$E)B]1W9F"+HY@%J\5]XMQ<(/M\ M7/Q;I,9YEKQ06)XS#60LUBSWI@WZ+J@7MT!'W-Y^E7+8#@M$M3F\PW_ 9 () MC[Y$=,>9 MD>,V!-0E6$#0_BRCU$'Z! MQ8STP61BV+RV3^F)*,0^8.>=.W;OG>_Q$)D>:-7=B*")FN\.WH_DC)EUZ W$ M]USU\009 ='7LT/)'_@-_?VZPBUS%.2Q6$CJ,-7&"S7AEY%$R&BU>FGN;%PH M8N]5R%MP0\[O6!C+7T?8'*KI""@Q?Q7!;+C_](&_CY%R"%[C-NP+Q4V$Z8=3 M3* ,7CT0,RO\LUB]T-_1GM]D+5H'"3L=JAH\.X12BV ?^7BA\B&L(T@JD6;I M,9WJW?(6K@39,.:VYM$O^F _2U,#PEMPA?-[[!H'E\Q# !UD]KGNL'#J7G@P M^NDPJDUQ8*&#(E<( :594P,%"!MP^'BP09\%&B_R!'Q@F-(UQ]BP4/X^7$R+ M$880!R-KZ/TNYC/M_^5S@!IXH&#JMNY\!TI,42NB5G<#\0H2;CJ>>,^+O("F M8NXP4C>RZ>"9 QT8#& P&A9 3-A3?DU,R\%7=C1;[XOJG7Z*3MS+1]E*'5NX M@#[5T=F'$PV5AJA3*?EG5@6[A(4NO8EYX5*81QG1'P;=#W1 ' MKH6DQ2E$@"H. 2!:"'XDXQC&%J=L!*L#9A?R%7Y&N1@?VC%-W"]WW"N$:J() M,F9R]?@/B?W+RSN']_&^=J+?_TN,>>YO\N4+3H[_J+ _.:S, %?F.R)?9O6- M $W#;/R@QN9-MX+[A>RU@IQ'AO+0%3M,TVUM.H8[32&A-10_8JN&3F@Q'#[% M&DI1B:FB)IPA-]O;@JKP[PA#TU=C>F@2OUO& M?" !P4SP,,]Z;+A:G7GMEUYII+>'6'OA2%I7-BG\+BP5T4<;FGOA*([!.5?] M@8\?<" F&BV!V0;Z%:R__W@?''J8]$A:AU0Q0&7C,1D\W!(:>H)RPGH)9A60 M 2Q/A)H!1T! 5I>L]@P#X!%P*KNU(UZE\6)*B&4UKP(S-$[;^6?6K(]\=V2%A=>K%91WCPG(7.L#P8& MWW2SGQ/W4@KO/)-\OT:BC++(%=.SCKMH94Y]?;:W,:,;>F^#W-O6C/T)P!*T M%]Q?1(Z>IROOGP_.1SJ/6B@WPZ&N8;20R/9,.7M85QI'K%Y5CN5ZM4H$?+ZB MFIZY3^'&_9^X*'KN*)N+O.V<>@N6%SB 'LY5!\O;ZXN/W59[^;JV_WES75/PF8BE6T^YKW,Y?SF^@);CU\P^ TF M='G1P8J2O7OX\564X+KYQ/QF:7!!)G,\_&:JTX$NTB35L5>32+A[K:FCF@-' M$CDM$]>OPBM"R&'17_^&HY0]^,]V@?C;>*B;]WCK>O&VXI59<.JLG#P4I-7- M 3>%Z/L1\83$X"CFH["#9;RU>:#E>:U%;OK@PT$%4XXK%[6U+I\7/A?$(A#2 M_'#0//#&4,=N=(AU,OUYPZZJE?VA[9@] /^['V%R\%=+E SL8LE CZ=C/$&" M%*ZMZD;"](ZL8V/_Z]@HW3KV]!\O6\6DJ!TQ,DD,_!3[^ +^V",77#;YP< & MU@?,?N@?5B6&_SO*A,N"(H5[EQ',UVI1(I1?<)1IY5^Z&#NM?&K")K!P&LIF M9]A/%F@X=JW)HFD9O/T;5XC;[\H>]DO2G2_**]U MOV!N\LY[Y:4+\2(IN1_]J)!^]%9=SJ=NK.]_U>NO>-5WW^LO78@<(2*%$-%S M]WK>T-!FOOFHQ#.6,QOW-UZ 7+'I>X\BFZ[PYE#;-H<-%X@Y;/C>G\.&*[PY MU+?-8<,%8@X;OO?GL.$*;PZ-;7/8<(&8PX;O_3FL7+$[1ZT))>#.5*IU":N> MP#^-QM'/F_R9(>];[RA'<%9H"Z165CRL;YXK [>L=@(CK'-8_;:>=U9&:[]9 MS-,3$; D)E"K2W*K&L>A, _3>K+5"6@9>[KJQTZ$!ANW86WO*YO ",]8V971 M]K:R2DNJ-T_B5K:6^D#0: HL4'I#XI5G+!$@VX]<4,8C4;,>* M,X(@":QE>JA#EMK-&H&./:YEBCA#:IVT"&;L<2U31!:2W(Q=RT("B[)X.NZX M&>F_4P9=1J2JV&0MZCGG^MEM23\V3(K;RYFH MC\D?U0M2\/9"W^0?&R;\[8>^B697+Z07[H6^R3\V3&;<#WT3S6->2)W<"WV3 M?VR8J)GV8JFQS 9%T7 MRKI&,1OO]R+K.M/D#(=CEU\!2P8 1PQK@A75"64DF?Y95RC]LQP@HR95Z[%) M,H0Q"H4Q6I)2;1/$* 7$:$C56FPPII (HRR.D)Z*[7/F_25U\X' 19*,7Y=3 MS-HD<+%7<"'78X48@8M"@0NY*M6J34(7)4$7 MC(UW&1<29I3%F]'1_I[JCHZ@@FEX[H&@18(BC&!%*6"%TB)040Y0(9/GHAR( M0I:45KE.3Y;%<7$^4LT'C@THAZINLT?5F(HS)AH\4X=O3!=_=?2!.%I)OHPD M=\6A(M6:V49-C@AP)"'=6C+5&2\'Y#AL2,UVMHZ,N#U)B.-YB$.)18^%1!QE M\6&LA$KT\02@QUA C1'X;E M$-+++=([;#4EI1F;,9-"%#*FU7RA0Y/E!'F'V'CH5%Y@Q*'2B;)_NS>;NRSK[=+B_A'TKQB3TCDF7_S9=P4!(9."_@ M($K\B5-?67J4]I_T4Q8WDW]\+UV<2)#PA7NJEF5%*7%@?(5&Y/F VMYIR'8CMD8P!; + M$\!N2*UVMBWX*(2])@^NC&BBG/[)FM2JI9A51W7%BNVFE!6IT4BQGP_5%2NV MM[(NU6HIXBRJ*E9LI^5F\4)5Q?*&]*ZYRPZQH-B1[T(J!=![.?_^5A#4=]C" MC19K.%%D.B>,DSO\UY).TG2 O2+XESCOY X+'K;:4E/)89)BH5UQR3-.[E!A M4VK%.VO+ PHIH$T!;0IH)VB,,-5U;;T_=57L;N9:##X<6R9S1JK-1Y8!PF=; M)60J5T;ERA8%U9[H2^7*J%S9HJ;8"WVI7%EAU-E'U=$UIIH#=J$;4YR^['VN0'&UA3=!7D.ZH7/]&L@<&4":)%QU3:!SDX0BYEPV[MTEW#, M.XK'4#R&XC$4CZ%X3%GB,65QAHAX3"E<(3L#M#R>9(N?;5V1ZLVJ),<;(_L_ MS_8B4[88?I!$N"9_K@^03-66(K7D#$^UE=@!D@C7Y,_G ;(&=5HMOOWV_@^W MO8AKBN']2(1K\N?PJ#6D9O-$DI442Q:0VX-B8 3\=X!@#_9%IANHX'PYN/W_\8^7UJ]4WZQ; _T2LI_@( M@.+BLZZ_?0T?%F4!C6.SQE,6&>#@[!;#6FWL"2W#0L%S<&JC$ '?=CYWCS_> M=3M_''<^W7?OWC'5>%)G3L (""U-OO#,4S;BWN04)+\/D'^MBO_686?_JY7W M^')QM_8]D!A+;Q$05LP_?(V45O'LO3Y^ +JX'P[T,9"S*E?^FCS U&UM\9.S M5&>V=HSE/;3#"!'2^QRT,.;[_MG'RYNKRT]=UKNY^G9_>7/=D]CE]7GE_=O^ M6>IS.;^YONA>][H7#'Z#"5U>=.[AC]X]_/C:O;[OL9M/\-77V[ON%[CN\M]= MG.O-URX[O+KI]8XRF?3A-U.=#G2PN22FCF%ON [V;'='UM11S8$C,?Y#XQ,W M&ECV+MLZWX29R@MD>WO_PT'U (2*8?AB-_S;F:A:^+>WFX>Z>8^WKI=RZZW7 M6+DO"*J; VX*"?A#V,H[6>X_;9-OQ!L7B49003H"(M_D=-@+Y\/_[D#QM,_7:QT0'H!(EMZ1=4PT1+E^'1NE M6\>>_N-EJYA^W);$P/-0?FR9BO2Y[)]3D[-:5=J[C'A)=[?B"XXRK?Q+%V.G ME4]-V 2&3D-YDV5, %'J9022'FU> F\[))JQ%VX');H=E->Z'90J=M[=<2N\ M="%>) 3WH_X44G_>JLOY5'V)9C>N7_7Z*U[UW??Z2Q-[!# M)=RHA%LT-9MRK.-*N'7O?0_TV\ #78*TFUS6O,F\ G3ISH5G?MX[]?+,YLN13 MI)0=S0[KS=BC/-38@GJ9S9/RLLO[+7$?BU*V,3MLQE>HH[X5U,!LNTPI3YN* MLOB:UN4]EMKK5,:"AZV:5)5C/1Y4\C OK)._XU_H*J.:AZGXS\I8\_"DBN? M\H0)J>IAGA!B_$2;4JL96Z3WE1\#HZ- *1\%^MBYZER?PQ2_=$7H]=/-W=<. MSC671W_H@$^>#OA00FN.\KLIJ;4D*W_!-3[NQ^$H:4 MW?^Z!6%^LOO)9Q[ZS%5G)#$-_F7\[ZG^J!JP?(XDNA3"#=^YAY@=KDUMW=7Y MMO:Z!?6D[^XAEY5]Y0[5FU*C%5N$*)7\S1+4-ON)),[]+6VS+9VT\M2]D/+" MPB88EOT=U 6(P(GNJD89Q-LST[OVQ_8G=:G52+&$8RDEVC-SL/:XF@VIWDJQ MM")E/NPLQ.XM$%U,=1SNE@*@Y4:"U5M5J18?52815BP1UFC4I6HCMD59(658 M#!"C$ZIK3ZB2S@CX\,HR'XY=;H^9U8<75UW=,DEY)"EM%("_S5AA0[JC6+JC M5I,:M13SR\B&WUF4=31M.IX:*O:R'/"AKNDN";(DSZK*8,DWZ[$.+#I;7A@I M=BA7&U(U_MQQ*G+LB-#8>@L^VCCW=Q&0<6=ED&0Y#;C(BE238P_X$$ K<,2E M?E*5Y%H.+7U*P"UY FY8BU^4XN_TOK!/5S=_]B@5EU)QGY&*6_@BVX6JT9X4 MM5-+K"P]^^0XC2U?-=HIEY=R>;/.ZJ1XZI3+FS,?TC5WO4S>J<,'B.VM M";=5%[/;5,W5'RE_=\^NU99T4H\]"$Q.\F)ZD@X;4KL:6W^N:/[RLH3\5F2= M;CYRIX2R+C]!0*4EU2@&6(88X(G4K*=8*Y$B@,^2:(>^2#MB$]MZU ?P1W_& MAKJIFAK)M_WMBGK\"1T2;H41;K63V"-TE*.5H7CK#H=<U];9?=2N7([2\%(Y;>S%JKEJ;]-:#.*-G53L[GJ<'8X MX-YO1VA):VM+ HB* #:8V+:N89ZMXUK:]U)([13*ZJ:U,S>4MZPW,G9.4EW= ME]75S0'OR'5)SO34W#;>R2BW;J _!EE)MY\__K$^(VGU9?Q/Q#J*CT /+#[K M^MO7C8'%R '9[?J X=?$5EC,BL\".=S]_CC7;?SQW'GTWWW[AU3 MC2=UY@0<@*K#Y L//64C[LU.0;WJ*\!?J^*_=;K1_VKE1;YZ^/'X N[H<#?0STK,J5OR8/,'5;6_SD+-69O<[$RKON^75I4B6Q#3*SYW.+?M\=]/KL=N[FT^7]^S^AEW?7!^++PX[%__\UKOO7APM M7$-9EI1E6?8TN2Q2/^Y'-N?9YEDNK^-^^G0WT^O37:ALV:2H3=FRKR!1+%_9 MLJ43'&5:^9?/.GE5:_O?]7KKWC5=]_K+UV( M' $>A0#/<_=Z3L!.V>.<*Y[#7 FUR2EGF7CSM=>3&-_*ZM(U68] M1UEU2RM;T"::F3?'/#A3:E);B=VS*?2\W+*R!>UQF7GO2EC9JM1JQ>[9Y)M2 M4B;L2R#)U\[=Y\OK,D"29R:U[HWO:]F6\TK4Z%@P,=YLX9)"P)MG)K3NCTNR MK>.:'9<4 BIMYI+TT%$M-ETR%624'9<4 G9MYI+TD%;\2W\.*U>0Z1 6.A>) MCEA&(GH_]$TT,KB@$/9"W^0?&ZJ?M+,;RQZ#NS0? MN>E:]@S&YI/CZ80<7@DZ>AO95APK?LPM+TZI5KSODF)LA7(<;=B3%%,KE'.G MU8RM)D,QM$PAA:N:#SJ>;1-=;_&L'1#B/U1+)@L4LO-D9:G:3C% ][(B(47$ M,/LI*),UNS1.8G-3\E)1IH@P*1%F20M-[3Q919+CV25YV)4(NQ0"BR7"+FE! MMF>H(KF58N2.ZE4E$?GH7KR"7.Z=63CCE._=MUI=:J190O 5P;[$F2=W&%"N M2;63W!<6+"0,3)QY\H<)FU*M&7#%@(+YL.WMRD?EG+KLP=]^7#J@2R)/9M&N?79H[M\^/) MEL06'2YI;GW:%8RIB.V^YA)3Q/;FMGL'GUQ_9MW_O>U>][J]N%*VJU=205LJ M:%OV2I94T+8<=2FIH"V)@32<=.ES&16TI94O5HTW*FB;\':@@K94T/85KSH5 MM'V-JTX%;5_CJE-!VYQ%N6.\B&6(<^>SK*W3G+<*@T);D=FX2G;P< M-SB43Z1&(]ON1'$+60@'3EY.!!PVT&<3>TP\%9]-W$(6PEV3EZ1](5JKV?8> M.DH.:93&2M;^GNJ.C@72F :HPR$XD:3P(B11>"2AM&)/>Q.,* R,D+/M9T@0 M(I%%E)16; W=HB&(LO@J2E]T-3=H0I%.XLO6$*(H#**0I9,3PA3%QQ0-J:7$ M(GR"%86!%2!7Y6P+NI-C8@567%F.PRR3#71G8CFJ@>$0@2_(0Y&L712KB0A1 M% =1Q(HO@A.%@1-*(]O45 (3R00>RX(DRN*@.!^IY@/'\C1#5;?9HVI,.:() M#9ZIPS>FB[\Z^H#;Y+-(NN>55&M2)[JRH RI%2_="&@4!6@TI&;\R34Z!%,P MN"$I2K;G7LAWL3TDHH\G #W& FJ,X Y>"B=&.;O1'3;;4KN:8F.2U:FN/_M> M:%=).5O1':>'AEY1!Y)2-J+;(E92P%W/%"N%P&'E[$(7*U:HO4C>H%[87H2* MKZ3G5*I*U5JV8:OB>Y5R67L%V[IE[&(J 7[*8^V56ELZB3_]05ZGI%4 MHDAR(\6&:+N"D[2;9@STQZ"KP.WGCW^LO*GH*+"*"?U/Q'*(CP#,+#[K^MO7 M\&'K2@U&!C@XNU4?.)-EC&_)M?=OX4$XMU$(TVX[G[O''^^ZG3^..Y_NNW?O MF&H\J3,G *>(?TR^\-!3-N+>[!0$ASZ*^[4J_EL'\/RO5E[DR\7=VA=!:BR] M1D!9,?_P-5):QK/W^O@!Z.)^.-#'0,^J7/EK\@!3M[7%3\Y2G1EU3%G;,05F M=O.URPZO;GJ]H^UM4Q8NI]XIU#NE[$T3J'=*.5H@4.\4$@-I.!_3YS+JG4(K M7ZQRXM0[)>'M0+U3J'?**UYUZIWR&E>=>J>\QE6GWBDY"^&O]2>^#1R$%,/? M3^)RJRDI=/:T9/'[P[K4:-!9U'*%[@]/:M))QB=&BIVDF,>P_6%#:M1*4_6" MFJ50LQ1JEO)R#!S;+,5#P]0J9=MCJ57*HDS:$WVI50JU2EE4"GNA+[5**8SF MNC0?N>E:]@S&YI/CZ:0,+IM\')D].%,:5+QCGRN9GF>F58NM'$O'*A)8R?3< M,1OV)!VC2& ETW/!M)K9^E_(&*:>**E#BFQ;HA"@2$P-9=P6A0!%8H=NLVV- M0G@BL87,O#T*.2FH1TJV#HO,6Z00PDA.G&7=)H4P1G(U1[-NE4(P(T$9FW&[ M%')<4,^4[#!&UBU3"&$DMI+9IJH2O$@N)I)MZQ0"%XEMR6S;IY #@WJHY UO M'&;?1*70)V5R@S8R;Y]"@"/!TQ-9-U$I])&8W,"-S-NGD"^#>JB4KH=*VBU4 M$FF.40@P0WU4\L JARCDG8;E43XI1"8C'JI9,(JY&3:T$N%BK&D9,W6 MZU2+I5RU6.(/%Y"O*>E53='Q)-=@KV9[ JC0GJ=<%F-I-&,1[>MIH$(]-/8U MEY@>&M?=^]VZ9ZQ<2'TSJ&]&)A6#J6]&C)J@OAEY6D?JFU$:,9#C8L+4-X-6 MOEBEI*EO1L+;@?IF4-^,5[SJU#?C-:XZ]4!$]0ZXR\(@IJG9&65J+6&:5!&-0ZHSP8@UIGE =F4.N,O,(,:IV1CKU$ MK3-*@C"HNE YX 6USB@+N*#6&;E$%M0Z(SN\0:TS2H(VJ'5&:0 'MYZFN9.MU6HM#TN[Q.= ?@S:(MY\__K'R MIJ(%XBK\\S\1:R$^ MRR^*SK;U_#AZWKC1 9X.#L5GW@3%8P)T8&=0@/PKF- M0D1VV_G\=4XTF=.0$.1:AC\H6'GK(1]V:G( [T =NO M5?'?.BSG?[7R(E\N[M:^"%)CZ34"RHKYAZ^1TC*>O=?'#T 7]\.!/@9Z5N7* M7Y,'F+JM+7YRENK,J,'K2QJ\=C]>WE]TJ*LK=77=[-DH?CM'ZNI:CN:,U-65 MQ$ :#L7TN8RZNM+*%ZO1&75U37@[4%=7ZNKZBE>=NKJ^QE6GKJZO<=6IJVO. MPO+4U96ZNE),_BZ(O-7"E!JZ+"F O]*4&KH714I?H6...R_B/"3<=_O90%U4YCB1F MBV^B1Y5^$I@)5.L\%6+K4!? M2-]+66Q@JO!%%;X(46P_K$<5ODH!**C"5SG@1,DJ?)7%5W'!)S;7=)5:G"3L MF3B)330@WT2AD(0LR=3DI"1@0I&:\>">_!.% A2R=!+?KX8\%'FJ&EJVWO#E MK!>:SIY*AQ2X9VI!:2HKMY:AB:+$KAH(RBN]E355#\P;Y M@DI%)3V.5*_%[@<*2Q7R.-*A+#4:L8M*(:J"'D5J2!MJ2E+ JI!'D0[; M]6RS8?;?G(8.(=$AI+T>0BH+UKVY_]*]8W04Z1F/I:-(=!1IK:BDHTAT%"F/ M1Y'*$HKKC52;'_=5AV.5HS$>1Q)1.'9H6N:QICJC4M20R4>D#9W<[8P;N10_ M6I:/,!AZH!OQ%44H[Z=0>3^R+-7H8%))$G_J4E6)K.%2D6C/; $FA#\CD!FU(+:JV4A+ <=B0FO$E.N@D3&'@AJ0H ML7ZI0B*.LO@RXA#'DVK;\#AFZ&I?-W1W1E CN>UP3(Z-4D"-V'4DF%$HF!&[ MCN35*!;,B&\"44B041:WQDHY-WT\ ;0Q%OZ,$=S!2Q$Y*6=1MV9;:E=CCS%0 M53>JZK8XV11!$55T*W9%M\VBA4JZ44FW'44+E7/+&^3SBEMT+UB9Z[HM,VX- M&'=@31'G+G%NQO7?=I^H+-7C'>[[!WNU\H*]Y+DG*^@7/]&:U*JF>#(I$>XI M!OY+GGNR0H/Q$VVV4NRLD CO% ,+)L\[62'##;PCU5LIYC2]C'M\>/@+_%3A M'ZP$1]:S [>_]VY(Z-L_\/4$L! A0#% M @ @H()5244'=81#@ >ET !0 ( ! &)I;VQI,C R M,C X,#E?.&LN:'1M4$L! A0#% @ @H()51KLQ0%W P +@X !$ M ( !0PX &)L9G,M,C R,C X,#DN>'-D4$L! A0#% @ @H() M55EZ.&7&UL4$L! A0#% @ @H()5?=7HN-1/@ #K8$ T J ( !SR$ &5X7S0P.3(X-"YH=&U02P4& 8 !@"% 0 2V end